Abstracts Archive - Page 2162 of 2425 - ACR Meeting Abstracts

Abstract Number: 1321 • 2013 ACR/ARHP Annual Meeting
Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis
Rosario Garcia-Vicuña¹, Ana M. Ortiz², Iria Valino-Seoane³, Amalia Lamana¹, Javier Leceta³, Yasmina Juarranz³, Isidoro González-Alvaro², Rosa P Gomariz³ and Carmen Martinez-Mora⁴, ¹Rheumatology, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, ²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ³Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, ⁴Cellular Biology, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The current shift to earlier treatment of Rheumatoid Arthritis (RA) has a major unmet need in the availability of biomarkers to identify patients requiring more…
Abstract Number: 1322 • 2013 ACR/ARHP Annual Meeting
Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir
Rachel Audo¹, Laura Papon¹, Claire I. Daien^1,2, Cédric Lukas³, Bernard Combe², Olivier Vittecoq⁴, Michael Hahne¹ and Jacques Morel⁵, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear factor…
Abstract Number: 1323 • 2013 ACR/ARHP Annual Meeting
Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis
Jung-Soo Song¹, You-Jung Ha², Eun-Jin Kang³, Kwang-Hoon Lee⁴, Sang-Won Lee⁵, Yong-Beom Park⁶, Soo-Kon Lee⁶ and Sang Tae Choi¹, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Dongguk University Ilsan Hospital, Goyang, South Korea, ⁵Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, ⁶Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats (LRRs). Though physiological functions of LRG have not been clarified yet, it has…
Abstract Number: 1324 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Usefulness Of Interferon-Gamma Release Assays and Tuberculin Skin Test For Detection Of Latent Mycobacterium Tuberculosis Infection In Korean Rheumatic Patients With Biologic Agents
Jae-Hoon Kim¹, Soyoung Won², Chan-Bum Choi³, Yoon-Kyoung Sung⁴, Gwan Gyu Song¹ and Sang-Cheol Bae⁵, ¹Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: The screening for and treatment of latent tuberculosis infection (LTBI) before starting biologic agents is crucial to prevent reactivation and resultant serious infection. Several…
Abstract Number: 1325 • 2013 ACR/ARHP Annual Meeting
A Novel Index To Identify Interstitial Lung Disease In Rheumatoid Arthritis Patients
Jose Felix Restrepo¹, Inmaculada Del Rincon², Roy W. Haas³, Daniel F. Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Rheumatology, University of Texas Health Science Center, San Antonio, TX, ³Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, ⁴Medicine / MCHE-MDR, San Antonio Military Medical Center, San Antonio, TX, ⁵Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
A Novel Index to Identify Interstitial Lung Disease in Rheumatoid Arthritis Patients José Félix Restrepo1, Inmaculada del Rincón1, Roy W Haas1, Daniel F Battafarano2, Agustín Escalante1…
Abstract Number: 1326 • 2013 ACR/ARHP Annual Meeting
Discriminative Metabolite Profiling Of Synovial Fluid In Rheumatoid Arthritis Compared To Osteoarthritis
Jiwon Hwang¹, Joong Kyong Ahn², Jaejoon Lee¹, Inyoung Kim¹, Seulkee Lee¹, Chan Hong Jeon³, Eun-Mi Koh¹ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea
Background/Purpose: Metabolomics is the study of unique chemical imprints that represent specific cellular processes in a cell, tissue, organ or organism. Synovial fluid in pathologic…
Abstract Number: 1327 • 2013 ACR/ARHP Annual Meeting
Autoantibodies To Citrullinated Proteins Associate With Bone Destruction Marker and Are Modulated By First Anti Rheumatic Treatment In Early Rheumatoid Arthritis
Aase Haj Hensvold¹, Vijay Joshua¹, Saedis Saevarsdottir², Michaela Larkin², Lena Israelsson², Ferhan Qureshi³, Per-Johan Jakobsson², Nadine A. Defranoux⁴, Lars Klareskog², Vivianne Malmström⁵ and Anca I Catrina², ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Crescendo Bioscience, Inc., South San Francisco, CA, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies against citrullinated proteins (especially anti citrullinated-vimentin antibodies) and high levels of RANKL have been linked to altered bone metabolism in early RA. We…
Abstract Number: 1329 • 2013 ACR/ARHP Annual Meeting
Physician Global Assessment At Three Months Is Strongly Predictive Of Remission At 12 Months In Early Rheumatoid Arthritis. Results From The Canadian Early Arthritis Cohort
Tommy Choy¹, Vivian P. Bykerk², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, J. Carter Thorne⁶, Edward C. Keystone⁷ and Janet E. Pope⁸, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To determine predictors of 1-year remission in early rheumatoid arthritis (ERA) using baseline and 3 months data. Methods: The Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: 1331 • 2013 ACR/ARHP Annual Meeting
Mathematical Model To Predict The Early Responders In a Monocentric Cohort Of Patients With Rheumatoid Arthritis Treated By Anti TNF-Alpha
Camillo Giacomelli¹, Claudia Ferrari¹, Chiara Stagnaro², Rosaria Talarico³, Arianna Consensi¹, Francesca Sernissi¹, Laura Bazzichi¹ and Stefano Bombardieri¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Pisa, Italy
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 1332 • 2013 ACR/ARHP Annual Meeting
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis
Elisa Gremese, Barbara Tolusso, Anna Laura Fedele, Maria Rita Gigante, Angela Carbonella, Silvia Canestri, Clara Di Mario and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Obesity per se is a systemic, low-grade inflammatory state and the adipose tissue is an endocrine organ that releases bioactive substances, including pro-inflammatory cytokines,…
Abstract Number: 1333 • 2013 ACR/ARHP Annual Meeting
The Impact Of Menopause In Rheumatoid Arthritis Activity
Sofia Pedro¹, Eliza Chakravarty², Megan E. B. Clowse³, Rebecca Schumacher¹ and Kaleb Michaud^1,4, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Rheumatology, Duke University Medical Center, Durham, NC, ⁴Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Factors such as menopause, hormonal replacement therapy (HRT), oral contraceptives (OC), pregnancy, and breast-feeding have been associated with the risk of developing Rheumatoid Arthritis…
Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Adrian Levitsky¹, Kristina Forslind^2,3 and Ronald F. van Vollenhoven⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund, Sweden, ³Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden
Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…
Abstract Number: 1335 • 2013 ACR/ARHP Annual Meeting
Sarcopenia Is Associated With Joint Damage In Rheumatoid Arthritis patients a Cross Sectional Study In a Peruvian Population
Erika Noriega¹, Rocio V. Gamboa-Cardenas¹, Manuel F. Ugarte-Gil^2,3, Mariela Medina-Chinchon², Francisco Zevallos-Miranda², J. Mariano Cucho-Venegas², Risto A. Perich-Campos^2,4, Jose L. Alfaro-Lozano², Zoila Rodriguez-Bellido^2,4 and Cesar A. Pastor-Asurza^2,4, ¹Rheumatology, Hospital Almenara, Lima, Peru, ²Rheumatology, Hospital Guillermo Almenara, EsSalud, Lima, Peru, ³Universidad Cientifica del Sur, Lima, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru
Background/Purpose: Sarcopenia is a low-level, smoldering inflammatory state driven by cytokines and oxidative stress. In rheumatoid arthritis (RA) the relationship between sarcopenia and severity of…
Abstract Number: 1336 • 2013 ACR/ARHP Annual Meeting
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Yukitomo Urata¹, Yoshihide Nakamura^2,3 and Ken-ichi Furukawa⁴, ¹Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ⁴Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To elucidate the safety and feasibility of a treat-to-target (T2T) strategy aimed at achieving a simplified disease activity index (SDAI) of ≤3.3 while administering…
Abstract Number: 1298 • 2013 ACR/ARHP Annual Meeting
Statin Alleviates Rheumatoid Arthritis Progression Through Diminishing Inflammation Or Oxidative Stress-Induced Cyr61 Synthesis
Kuo Liang Hou and Sze Kwan Lin, School of Dentistry, College of Medicine National Taiwan University, Taipei, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease stimulated by inflammatory mediators and oxygen species within joint space cause joint deformity and destruction. Excess amounts…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].